Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-19
DOI
10.1038/s41467-019-12996-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine
- (2018) Yu Muta et al. Nature Communications
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2
- (2017) Andrea Piserchio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
- (2016) D. Oddo et al. CANCER RESEARCH
- Negative feedback regulation of the ERK1/2 MAPK pathway
- (2016) David Lake et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf
- (2015) Ramin Samadani et al. BIOCHEMICAL JOURNAL
- Structure-Based Assignment of Ile, Leu, and Val Methyl Groups in the Active and Inactive Forms of the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 2
- (2015) Yao Xiao et al. BIOCHEMISTRY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Differential Sensing of MAP Kinases Using SOX-Peptides
- (2014) Diana Zamora-Olivares et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
- (2014) Lydia W.T. Cheung et al. CANCER CELL
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine
- (2014) Mangalika Warthaka et al. ACS Medicinal Chemistry Letters
- Stochastic ERK Activation Induced by Noise and Cell-to-Cell Propagation Regulates Cell Density-Dependent Proliferation
- (2013) Kazuhiro Aoki et al. MOLECULAR CELL
- Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling
- (2013) Kwan-Young Jung et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Molecular basis of MAP kinase regulation
- (2013) Wolfgang Peti et al. PROTEIN SCIENCE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Manipulating JNK Signaling with (−)-Zuonin A
- (2012) Tamer S. Kaoud et al. ACS Chemical Biology
- Docking Interactions of Hematopoietic Tyrosine Phosphatase with MAP Kinases ERK2 and p38α
- (2012) Andrea Piserchio et al. BIOCHEMISTRY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals
- (2012) John G. Albeck et al. MOLECULAR CELL
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Bond Activation with an Apparently Benign Ethynyl Dithiocarbamate ArCCSC(S)NR2
- (2011) Gaël Ung et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Activated ERK2 Is a Monomer in Vitro with or without Divalent Cations and When Complexed to the Cytoplasmic Scaffold PEA-15
- (2011) Tamer S. Kaoud et al. BIOCHEMISTRY
- Solution NMR Insights into Docking Interactions Involving Inactive ERK2
- (2011) Andrea Piserchio et al. BIOCHEMISTRY
- Examining Docking Interactions on ERK2 with Modular Peptide Substrates
- (2011) Sunbae Lee et al. BIOCHEMISTRY
- Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
- (2011) Sarice R Boston et al. BMC CANCER
- Understanding the Specificity of a Docking Interaction between JNK1 and the Scaffolding Protein JIP1
- (2011) Chunli Yan et al. JOURNAL OF PHYSICAL CHEMISTRY B
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Global quantification of mammalian gene expression control
- (2011) Björn Schwanhäusser et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- 193-nm photodissociation of singly and multiply charged peptide anions for acidic proteome characterization
- (2011) James A. Madsen et al. PROTEOMICS
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
- (2010) C. Bartholomeusz et al. CLINICAL CANCER RESEARCH
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
- (2008) J. L. Stebbins et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search